The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis
Open accessAbstract
Low-contrast letter acuity (LCLA) has emerged as the leading outcome measure to assess visual disability in multiple sclerosis (MS) research. As visual dysfunction is one of the most common manifestations of MS, sensitive visual outcome measures are important in examining the effect of treatment. Low-contrast acuity captures visual loss not seen in high-contrast visual acuity (HCVA) measurements. These issues are addressed by the MS Outcome Assessments Consortium (MSOAC), including representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with MS. MSOAC goals are acceptance and qualification by regulators of performance outcomes that are highly reliable and valid, practical, cost-effective, and meaningful to persons with MS. A critical step is elucidation of clinically relevant benchmarks, well-defined degrees of disability, and gradients of change that are clinically meaningful. This review shows that MS and disease-free controls have similar median HCVA, while MS patients have significantly lower LCLA. Deficits in LCLA and vision-specific quality of life are found many years after an episode of acute optic neuritis, even when HCVA has recovered. Studies reveal correlations between LCLA and the Expanded Disability Status Score (EDSS), Multiple Sclerosis Functional Composite (MSFC), retinal nerve fiber layer (RNFL) and ganglion cell layer plus inner plexiform layer (GCL + IPL) thickness on optical coherence tomography (OCT), brain magnetic resonance imaging (MRI), visual evoked potential (VEP), electroretinogram (ERG), pupillary function, and King-Devick testing. This review also concludes that a 7-point change in LCLA is clinically meaningful. The overall goal of this review is to describe and characterize the LCLA metric for research and clinical use among persons with MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Cohen, J. A., Reingold, S. C., Polman, C. H., & Wolinsky, J. S. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70059-5 · Cited by 233
Burkholder, B. M., Osborne, B., Loguidice, M. J., Bisker, E., Frohman, T. C., Conger, A., Ratchford, J. N., Warner, C., Markowitz, C. E., Jacobs, D. A., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.230 · Cited by 199
Self-citation
Cited by
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
Benedict, R. H. B., Amato, M. P., DeLuca, J., & Geurts, J. J. G. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30277-5 · Cited by 764
Self-citationOptic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment
Bennett, J. L., Costello, F., Chen, J. J., Petzold, A., Biousse, V., Newman, N. J., & Galetta, S. L. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00187-9 · Cited by 226
Self-citationNolan‐Kenney, R. C., Liu, M., Akhand, O., Calabresi, P. A., Paul, F., Petzold, A., Balk, L., Brandt, A. U., Martínez‐Lapiscina, E. H., Saidha, S., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25462 · Cited by 164
Self-citationDiagnosis and Management of Progressive Multiple Sclerosis
Macaron, G., & Ontaneda, D. (2019) · Biomedicines · doi:10.3390/biomedicines7030056 · Cited by 70
Wicki, C. A., Hanson, J. V. M., & Schippling, S. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000604 · Cited by 16
Metadata
- Authors
- Balcer, L. J., Raynowska, J., Nolan, R., Galetta, S. L., Kapoor, R., Benedict, R., Phillips, G., LaRocca, N., Hudson, L., Rudick, R., & Multiple Sclerosis Outcome Assessments Consortium
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2017-02-16
- Volume
- 23
- Issue
- 5
- Pages
- 734-747
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2588929689
- Cited by
- 168
- References
- 3
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. https://app.cochat.ai/papers/10.1177/1352458517690822
- The paper
- Balcer, L. J., Raynowska, J., Nolan, R., Galetta, S. L., Kapoor, R., Benedict, R., Phillips, G., LaRocca, N., Hudson, L., Rudick, R., & Multiple Sclerosis Outcome Assessments Consortium. (2017). Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458517690822
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.